UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1 Clinical Trials: Challenges and Opportunities in Latin America

Journal of Immunotherapy and Precision Oncology, 2024-08, Vol.7 (3), p.168-170

2024

Volltextzugriff (PDF)

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Molecular cancer, 2024-03, Vol.23 (1), p.64-64, Article 64

2024

Volltextzugriff (PDF)

Learning From Failure: Negative Trials in Oncology

Journal of Immunotherapy and Precision Oncology, 2023-05, Vol.6 (2), p.59-60

2023

Volltextzugriff (PDF)

Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma

Pathology oncology research, 2020-10, Vol.26 (4), p.2489-2497

2020

Volltextzugriff (PDF)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

NPJ precision oncology, 2023-05, Vol.7 (1), p.47-47, Article 47

2023

Volltextzugriff (PDF)

Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

Hematology, Transfusion and Cell Therapy, 2021-11, Vol.43 (Suppl 2), p.S78-S83

2021

Volltextzugriff (PDF)

Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience

Journal of hematology, 2022-06, Vol.11 (3), p.113-120

2022

Volltextzugriff (PDF)

Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate at a public hospital in Brazil

Brazilian Journal of Oncology, 2021-10, Vol.17

2021

Volltextzugriff (PDF)

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?

Ecancermedicalscience, 2019-11, Vol.13, p.973

2019

Volltextzugriff (PDF)

Primary splenic angiosarcoma: a rare entity often associated with rupture and hemoperitoneum

Autopsy & case reports, 2019-07, Vol.9 (3), p.e2019100

2019

Volltextzugriff (PDF)

Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis (309)

Gynecologic oncology, 2022-08, Vol.166, p.S162-S163

2022

Volltextzugriff (PDF)

Real-world comparative Analysis of Liposomal Doxorubicin versus Paclitaxel as First-Line Therapy for Kaposi Sarcoma

Journal of acquired immune deficiency syndromes (1999), 2024-11

2024

Volltextzugriff (PDF)

Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis

Gynecologic oncology, 2022-06, Vol.165 (3), p.664-670

2022

Volltextzugriff (PDF)

RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3105-3105

2023

Volltextzugriff (PDF)

Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14532-e14532

2023

Volltextzugriff (PDF)

Adoptive Cell Therapy in Gynecologic Cancers: A Systematic Review and Meta-analysis

Obstetrical & gynecological survey, 2022-09, Vol.77 (9), p.533-534

2022

Volltextzugriff (PDF)

Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5611-5611

2023

Volltextzugriff (PDF)

Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3086-3086

2023

Volltextzugriff (PDF)

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2564-2564

2023

Volltextzugriff (PDF)

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Clinical cancer research, 2024-07, Vol.30 (14), p.2986-2995

2024

Volltextzugriff (PDF)

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (8), p.714-721

2023

Volltextzugriff (PDF)

Cannabidiol reverses the mCPP-induced increase in marble-burying behavior

Fundamental & clinical pharmacology, 2014-10, Vol.28 (5), p.544-550

2014

Volltextzugriff (PDF)

Abstract 2764: Safety and efficacy of CAR T and TCR therapies in solid tumors: A systematic review and meta-analysis, including a comparison with five phase II trials in hematologic malignancies used for the first FDA approvals of these agents

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2764-2764

2022

Volltextzugriff (PDF)

CA209-9JC: A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic cutaneous squamous cell carcinoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10044-10044

2020

Volltextzugriff (PDF)

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

Cell reports. Medicine, 2023-12, Vol.4 (12), p.101332, Article 101332

2023

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(37)

Publikationsform

Sprache

Englisch
(43)
Italienisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase 1 Clinical Trials: Challenges and Opportunities in Latin America

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Learning From Failure: Negative Trials in Oncology

Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience

Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate at a public hospital in Brazil

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?

Primary splenic angiosarcoma: a rare entity often associated with rupture and hemoperitoneum

Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis (309)

Real-world comparative Analysis of Liposomal Doxorubicin versus Paclitaxel as First-Line Therapy for Kaposi Sarcoma

Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis

RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study

Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials

Adoptive Cell Therapy in Gynecologic Cancers: A Systematic Review and Meta-analysis

Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers

Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience

Cannabidiol reverses the mCPP-induced increase in marble-burying behavior

Abstract 2764: Safety and efficacy of CAR T and TCR therapies in solid tumors: A systematic review and meta-analysis, including a comparison with five phase II trials in hematologic malignancies used for the first FDA approvals of these agents

CA209-9JC: A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic cutaneous squamous cell carcinoma

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

Suchergebnisse filtern